海马保护全脑放疗同期推量治疗NSCLC多发脑转移Ⅱ期试验
单臂前瞻性Ⅱ期研究纳入23例NSCLC多发脑转移(≥4个病灶)患者,接受HA-WBRT(30 Gy/12次)+SIB(48 Gy/12次)。放疗后1个月可评价的159个病灶中完全缓解66.7%,治疗相关不良反应发生率26.1%,HVLT-R DR评分放疗前后差异有统计学意义(P<0.001),中位iPFS为11.1个月。
要点
- HA-WBRT+SIB在NSCLC多发脑转移中颅内病灶完全缓解率达66.7%。
- 治疗相关不良反应发生率26.1%,仅1例出现4级记忆障碍。
- HVLT-R DR评分放疗后2、4个月较放疗前下降,差异有统计学意义(P<0.001)。
核心结论
- HA-WBRT+SIB治疗NSCLC多发脑转移可改善颅内肿瘤控制并保护认知功能,是安全有效的治疗选择。
研究设计与样本
- 单臂前瞻性Ⅱ期临床研究,入组2021年1月至2023年6月南京医科大学附属肿瘤医院收治的NSCLC多发脑转移(≥4个转移灶)患者23例。
- 所有患者接受海马保护下全脑放疗(30 Gy/12次,海马最大剂量≤17 Gy、平均剂量≤12 Gy)+SIB(48 Gy/12次)。
主要发现
- 放疗后1个月可评价的22例患者159个局部推量脑转移灶中,完全缓解106个(66.7%),部分缓解37个(23.3%),疾病稳定12个(7.5%),疾病进展4个(2.5%)。
- 3例患者出现SIB脑转移灶区域内进展,3例出现SIB区域外进展,其中1例在海马保护区内出现2个新转移灶。
- 治疗相关不良反应发生率为26.1%(6/23),其中仅1例出现4级记忆障碍。
- 放疗前、放疗后2个月和4个月的HVLT-R DR评分分别为14.9(13.3,15.1)分、14.1(12.9,14.6)分和13.7(13.1,13.8)分,差异有统计学意义(P<0.001)。
- 中位随访11.1个月,中位iLPFS为16.4个月,中位iPFS为11.1个月,1年颅内局部失败累积发生率为9.6%。
关键数值与推荐
- 海马保护下全脑放疗剂量30 Gy/12次,海马最大剂量≤17 Gy、平均剂量≤12 Gy,SIB剂量48 Gy/12次。
- 疗效评价采用国际神经肿瘤学工作组神经肿瘤脑转移反应评价标准,不良反应采用CTCAE5.0,认知功能采用HVLT-R DR评分。
临床怎么用
- 对于NSCLC多发脑转移(≥4个病灶)患者,可考虑采用HA-WBRT+SIB方案以兼顾颅内病灶控制与认知功能保护。
- 治疗中需关注海马保护区新发转移及记忆障碍等不良反应,并进行认知功能随访评估。
局限性
- 本研究为单臂Ⅱ期研究,样本量较小(23例),缺乏同期对照组。
- 中位随访时间较短(11.1个月),长期疗效与认知功能变化需进一步随访验证。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Objective: To explore the safety and feasibility of hippocampus-avoidance whole-brain radiation therapy with simultaneous integrated boost (HA-WBRT+SIB) in the treatment of multiple brain metastases ( ≥4 lesions) in non-small cell lung cancer (NSCLC). Methods: In this prospective, single-arm phase Ⅱ clinical study, twenty-three patients with multiple brain metastases of NSCLC were enrolled in the Affiliated Cancer Hospital of Nanjing Medical University from January 2021 to June 2023. All patients received HA-WBRT (30 Gy/12 fractions, with the maximum dose to the hippocampus ≤ 17 Gy and the average dose ≤ 12 Gy) + SIB (48 Gy/12 fractions). Patients were assessed for the therapeutic effect by the response evaluation criteria for brain metastases of the International Society for Neuro-Oncology, adverse reactions by Common Terminology Criteria for Adverse Events 5.0 (CTCAE5.0), cognitive function by the Hopkins Verbal Learning Test-Revised Delayed Recall (HVLT-R DR) 2 and 4 months after radiotherapy, as well as before radiotherapy. The patients' intracranial local progression-free survival (iLPFS), intracranial progression-free survival (iPFS), and intracranial tumor control were followed up. Results: One month after radiotherapy, among the 172 local tumor brain metastases of the 23 patients, 13 lesions were lost to follow-up. The remaining 159 lesions showed the following outcomes: 106 lesions (66.7%) achieved complete remission, 37 lesions (23.3%) achieved partial remission, 12 lesions (7.5%) showed stable disease, and 4 lesions (2.5%) had disease progression. Three patients had intraregional progression in the brain metastases and three patients had extraregional progression (one patient of the three patients developed two new metastases within the hippocampal avoidance area). The incidence of treatment-related adverse reactions was 26.1% (6/23), among which only one patient experienced grade 4 memory impairment. The HVLT-R DR scores before and 2 and 4 months after radiotherapy were 14.9 (13.3, 15.1) points, 14.1 (12.9, 14.6) points, and 13.7 (13.1, 13.8) points respectively, and the difference was statistically significant (P<0.001). The median follow-up period was 11.1 months. The median iLPFS was 16.4 months and the median iPFS was 11.1 months. The cumulative incidence of local failure in the brain region over one year was 9.6%. Conclusion: For patients with multiple brain metastases of NSCLC, HA-WBRT+SIB emerges as a promising and safe therapeutic alternative, protecting cognitive function and demonstrating improved intracranial tumor control. 目的: 探讨海马保护下全脑放疗同期推量(HA-WBRT+SIB)治疗非小细胞肺癌(NSCLC)多发脑转移瘤的效果与安全性。 方法: 这是一项单臂前瞻性Ⅱ期临床研究。入组2021年1月至2023年6月南京医科大学附属肿瘤医院收治的NSCLC多发脑转移(≥4个转移灶)患者23例,均接受海马保护下全脑放疗(30 Gy/12次,海马的最大剂量≤17 Gy,平均剂量≤12 Gy)+SIB(48 Gy/12次)。依据国际神经肿瘤学工作组制定的神经肿瘤脑转移反应评价标准进行疗效评价,依据不良事件通用术语标准5.0评价不良反应,分别在放疗前、放疗后2个月和4个月时对患者进行霍普金斯词语学习测试-修订版延迟回忆(HVLT-R DR)评分以评估认知功能。随访患者的颅内无局部进展生存时间(iLPFS)、颅内无进展生存时间(iPFS)和颅内肿瘤控制情况。 结果: 放疗后1个月能评价疗效的22例患者的159个局部推量脑转移灶中,完全缓解106个(66.7%),部分缓解37个(23.3%),疾病稳定12个(7.5%),疾病进展4个(2.5%)。3例患者出现SIB脑转移灶区域内进展,3例患者出现SIB区域外进展,其中1例患者在海马保护区内出现了2个新转移灶。治疗相关不良反应发生率为26.1%(6/23),其中仅1例患者出现了4级记忆障碍。放疗前、放疗后2个月和4个月的HVLT-R DR评分分别为14.9(13.3,15.1)分、14.1(12.9,14.6)分和13.7(13.1,13.8)分,差异有统计学意义(P<0.001)。中位随访11.1个月,23例患者中有9例患者死亡。中位iLPFS为16.4个月,中位iPFS为11.1个月,1年颅内局部失败的累积发生率为9.6%。 结论: HA-WBRT+SIB治疗NSCLC多发脑转移,可以改善颅内肿瘤控制,同时保护患者的认知功能,是NSCLC多发脑转移患者的一种安全、有效的治疗选择。.
引用
- Li YT, Gao H, Wang DD, et al. [Hippocampus-avoidance whole-brain radiation therapy with simultaneous integrated boost for multiple brain metastases in non-small cell lung cancer: a phase Ⅱ trial]. Zhonghua Zhong Liu Za Zhi. 2026. PMID: 42151089. doi:10.3760/cma.j.cn112152-20250306-00092
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。